Auna S.A. reports developments for a Latin American healthcare platform operating in Mexico, Peru and Colombia. The company combines a network of hospitals, ambulatory centers, prevention and wellness facilities with oncology and selected general health plans, with segment reporting around Oncosalud Peru and healthcare services in Peru, Colombia and Mexico.
Recurring news covers quarterly financial results, key performance indicators, operating trends by country, capital structure actions, debt refinancing, public-private partnership activity such as Torre Trecca in Lima, and strategic healthcare collaborations. Updates also include Form 20-F reporting dates and financial guidance tied to its integrated services-and-plans model.
Auna (AUNA) now expects full-year 2026 Adjusted EBITDA to be broadly stable year over year, lowering its preliminary outlook.
The prior expectation was growth at the lower end of 10% to 14% FX-neutral, excluding one-time effects primarily related to payor billing penalties on prior-year receivable reconciliations. A Colombian payor contract has added temporary cost pressure from unexpectedly high advanced-stage cancer incidence. Auna still expects revenue growth in line with earlier guidance, supported by Mexico’s second-half recovery. Capital expenditures remain within guidance of approximately 4.0% of consolidated revenue. The company describes Free Cash Flow and leverage trends as favorable and will give further contract-related details on its third-quarter earnings call.
Auna (AUNA) has fulfilled all conditions required to begin construction of Centro Ambulatorio Trecca under its public-private partnership with EsSalud.
Following EsSalud’s formal confirmation, the Lima outpatient project will enter its investment and construction phase. Auna expects operations to begin in late 2028. The partnership opens access to approximately six million EsSalud-insured Lima residents.
The concession has an initial 20-year term, potentially extendable for another 20 years. Once operational, EsSalud will make monthly payments based on a guaranteed minimum service volume. Construction spending will be reimbursed through payments linked to certificates for defined construction milestones.
Auna (AUNA) reported preliminary operating indicators for the third quarter ended September 30, 2026, showing higher hospital activity across its three countries. Surgeries reached 5,807 in Mexico, 6,107 in Peru and 12,018 in Colombia, above third-quarter 2025 levels. Bed capacity utilization rose year over year to 41.1%, 89.2% and 80.3%, respectively.
OncoSalud Peru memberships were 1,441,794, above 1,395,509 a year earlier but below 1,472,019 in the second quarter. Colombia’s protected lives reached 3,208,686, up from 3,027,499 a year earlier. Mexico’s chemotherapy and radiotherapy sessions increased year over year but declined sequentially. The indicators remain preliminary and subject to review, verification and possible revision.
Auna (AUNA) will release its third-quarter 2026 financial results after market close on November 17, 2026, followed by a conference call.
The call is scheduled for November 18, 2026, at 8:00 a.m. ET. The quiet period runs from November 2 through November 17, 2026.
Auna (AUNA) will host its first Investor Day on Thursday, October 22, 2026, in a hybrid format in Lima, Peru and via live webcast.
The event targets investors and sell-side analysts, with on-site registration and breakfast at 9:00 a.m. ET and management presentations, webcast and Q&A starting at 10:00 a.m. ET. In-person attendees will have a luncheon and a tour of Clinica Delgado and Wellness Center, subject to capacity. Management plans to discuss long-term vision, growth and financial strategies, and priorities for profitable growth across Mexico, Peru and Colombia.
Auna (NYSE: AUNA) reported 2Q26 revenue of S/1,238 million, up 9% FX-neutral and 13% YoY, with local-currency growth of 4% in Mexico, 8% in Peru and 13% in Colombia. Adjusted EBITDA was S/227 million, down 9% FXN and 6% YoY, but up 3% FXN versus 1Q26, for a margin of 18.4%.
Operating cash flow rose 45% YoY and free cash flow 181% YoY, improving the leverage ratio to 3.6x. Net finance costs increased to S/105 million, mainly from lower non-cash FX gains, driving net income down to S/33 million (S/0.40 per share) and Adjusted Net Income to S/40 million (S/0.50 per share). Auna reaffirmed 2026 FX-neutral revenue growth guidance near 12%, expects Adjusted EBITDA growth at the low end of its 10–14% range, maintains capex at about 4% of revenues, and anticipates free cash flow above internal expectations.
Auna (NYSE: AUNA) announced the schedule for its Second Quarter 2026 financial results. The earnings release will be issued on Tuesday, August 18, 2026, after market close, followed by a conference call on Wednesday, August 19, 2026 at 8:00 a.m. ET.
The company will observe a quiet period from Monday, August 3 through Tuesday, August 18, 2026. Investors can join the call via toll-free and international dial-in numbers using passcode 3884034 or through a webcast.
Auna (NYSE:AUNA) reported preliminary key performance indicators for the second quarter ended June 30, 2026, covering its healthcare operations in Mexico, Peru, and Colombia, plus OncoSalud in Peru. The disclosure includes emergency treatments, surgeries, hospitalized days, capacity utilization, oncology sessions, plan memberships, and protected lives.
In 2Q26, Mexico reported 7,892 emergency treatments, 5,193 surgeries, 25,169 hospitalized days, 39.1% capacity utilization, and 4,994 chemotherapy and radiotherapy sessions. Peru’s healthcare services recorded 51,769 emergency treatments, 5,552 surgeries, 28,395 hospitalized days, 80.2% utilization, and 12,957 oncology sessions, while OncoSalud plan memberships reached 1,472,019. Colombia reported 38,196 emergency treatments, 11,167 surgeries, 81,558 hospitalized days, 79.2% utilization, 3,143,694 protected lives, and 39,628 oncology sessions.
Auna (NYSE:AUNA) reported 1Q26 revenue of S/1,178 million, up 10% FXN and 13% YoY. Adjusted EBITDA was S/217 million, down 5% FXN with an 18.4% margin.
Operating cash flow rose 48% YoY, organic free cash flow grew 2.6x, leverage stayed at 3.7x, and full-year 2026 revenue and Adjusted EBITDA guidance were reaffirmed.
Auna (NYSE: AUNA) announced it filed its Annual Report on Form 20-F for fiscal year ended December 31, 2025 with the SEC on April 21, 2026. The company said shareholders can access the filing on the SEC website or the company’s Investor Relations “Financial Info” page.
Shareholders may request a free hard copy of the audited financial statements or the complete 2025 Form 20-F by contacting the Investor Relations team at contact@aunainvestors.com.